As part of an ongoing quest to reform the pharmaceutical industry, the Federal Trade Commission reached a sweeping settlement with Teva Pharmaceuticals (TEVA), one of the largest generic suppliers, over so-called pay-to-delay deals that the agency says greatly increase consumer drug costs.

The agreement resolves three pending cases against Teva and significantly expands a settlement reached four years ago in another case that at the time was considered a landmark. In that deal, Teva paid $1.2 billion to resolve claims a subsidiary violated antitrust law, the first time the FTC recovered money on behalf of consumers and others who pay for medicines, such as pharmacies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Bemusing closing note – re AbbVee, not TEVA: “but the companies insist nothing of value was involved.” Hmmm ……
    Was it really just a Seinfeld deal? You know, “a deal about nothing?”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy